Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical trial NCT01395758 · COMPLETED

Trial details

NCT number: NCT01395758
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Non-Small Cell Lung Cancer

Start date: 2011-07-01
Primary completion: 2016-08-01
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.